|
1
|
A study on framework of a new remote personalized oral anticancer medication self-management model for patients with haematological malignancies (FRGS grant). |
|
2
|
A phase ib/ii single arm, open label trial to assess the efficacy and safety of chimeric antigenrreceptor (car)- t cell therapy targeting the CD19 Antigen (Auxicart-19) for patient with relapsedor refractory aggractory aggressive b-cell lymphoma in Malaysia (in kind grant). |
|
3
|
Significance of HOXA9, HOXA11 and PRMT8 proteins overexpression in patients with RCHOP chemotherapy-resistant diffuse large B-cell lymphoma (MSH grant). |
|
4
|
Unraveling the Diagnostic and Therapeutic Potential of Cell-Free Extrachromosomal Circular DNA in Diffuse Large B Cell Lymphoma: A Novel Approach. |
|
5
|
MG011-2024 Developing An Online Course On Chronic Myeloid Leukaemia For Postgraduate Medical Students. |
|
1
|
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide.
|
|
2
|
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma.
|
|
3
|
An open-label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV) Relapsed/Refractory Lymphomas (NAVAL-1)
|
|
4
|
Phase 3 Study of Nemtabrutinib vs Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) for 1L CLL/SLL.
|
|
5
|
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL).
|
|
6
|
A Multicenter Retrospective Study To Understand The Clinical Characteristics, Treatment Pathway And Resource Utilization For Patients With Chronic Lymphocytic Leukemia (CLL).
|
| 7 |
MOM-M281-006 efficacy and safety of M281 in adults with warm autoimmune hemolytic anemia: a multicenter, randomized, double-blind, placebo-controlled study with a long-term open-label extension.
|
| 8 |
CABL001J12302 a phase IIIB, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patines with newly diagnosed Philadelphia chromosome psitive chronic myelogeneous leukemia in chronic phase.
|
| 9 |
A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 versus Best Available Therapy in Subjects with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or PostEssential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/ L).
|
| 10 |
A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in.
|
| 11 |
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients.
|
| 12 |
A Multicenter Retrospective Study To Understand The Clinical Characteristics, Treatment Pathway And Resource Utilization For Patients With Chronic Lymphocytic Leukemia (CLL).
|
| 13 |
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract.
|
| 14 |
A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2).
|
Last Update: 05/11/2024